While survival declines sharply with advancing age in IDH-wildtype glioblastoma, the impact of age in IDH-mutant astrocytomas and oligodendrogliomas is more nuanced, with molecular alterations playing a dominant role in shaping clinical outcomes rather than age alone. The gene discussed is IDH2; the disease is glioblastoma.